Experience

Davis Polk is advising Gilead Sciences, Inc. in its acquisition of Immunomedics, Inc. for $88.00 per share in cash. The transaction, which values Immunomedics at approximately $21 billion,…

Davis Polk advised the underwriters in connection with the initial public offering of 30,000,000 units of Prime Impact Acquisition I, for aggregate proceeds of $300 million. Each unit…

Davis Polk advised the representative of the initial purchasers in connection with a Rule 144A/Regulation S offering by Quicken Loans, LLC of $750 million aggregate principal amount of its…

Davis Polk advised Arco Platform Limited on its SEC-registered follow-on offering of an aggregate of 2,500,000 Class A common shares issued and sold by Arco at a price per Class A common…

Davis Polk advised the underwriters in connection with a block trade of 9,180,568 shares of common stock of Intercontinental Exchange, Inc. by a selling shareholder. The shares sold in…

Davis Polk advised the joint bookrunners in connection with the initial public offering by JSL S.A. of 72,255,762 common shares for an aggregate amount of approximately R$693.7 million. The…

Davis Polk advised MDLIVE Inc. in connection with its private placement of approximately $50 million in shares of its Series F preferred stock.MDLIVE offers virtual healthcare services to…

Davis Polk advised the dealer manager in connection with a cash tender offer by Rackspace Technology Global, Inc., an indirect subsidiary of Rackspace Technology, Inc., for up to $600…

Davis Polk advised the initial purchasers in connection with a Regulation S offering by Zhenro Properties Group Limited of $350 million 7.350% senior notes due 2025. Zhenro Properties Group…

Davis Polk advised the joint bookrunners on an offering of $1 billion aggregate principal amount of 2.625% senior notes due 2025 and $500 million aggregate principal amount of 3.950% senior…